FDA Expands Spevigo Approval to Include Teens With GPP
The U.S. Food and Drug Administration (FDA) has approved spesolimab-sbzo (Spevigo, Boehringer Ingelheim) injection for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and above weighing ≥40 kg. This approval follows the Chinese National Medical Products Administration’s (NMPA) recent approval of spesolimab-sbzo for the reduction of occurrence of GPP […]